Results 41 to 50 of about 15,585 (162)

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study

Platelets, 2020
Patients treated with ticagrelor and aspirin usually suffer from bleeding events, especially mild bleeding which is one of the main factors reducing patients’ adherence to ticagrelor.
Jiannan Li, Zhaoxue Sheng, Yu Tan, Chen Liu, Peng Zhou, Jinying Zhou, Runzhen Chen, Yi Chen, Li Song, Hanjun Zhao, Hongbing Yan   +10 more
doaj   +1 more source

Evaluating the impact of a newly established hospitalist medicine procedure service on length of stay and procedural outcomes: A retrospective propensity‐matched analysis

Journal of Hospital Medicine, EarlyView.
Abstract Background Reliance on interventional radiology (IR) has been associated with delays in procedure completion and prolonged hospital length of stay (LOS). Hospitalist medicine procedure services (HMPS) have been proposed as a strategy to mitigate these inefficiencies, though outcomes of newly established programs composed of physicians with ...
Jeremy Gentile, Saria Alazmeh, Kriti Soni, Tarek Alsibai, Felicia Wright, Alicia Stowe, Fergus Peacock   +6 more
wiley   +1 more source

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Ticagrelor is a P2Y12 receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high‐dose aspirin.
Sukhdeep S. Basra, Tracy Y. Wang, DaJuanicia N. Simon, Karen Chiswell, Salim S. Virani, Mahboob Alam, Vijay Nambi, Ali E. Denktas, Anita Deswal, Biykem Bozkurt, Christie M. Ballantyne, Eric D. Peterson, Hani Jneid   +12 more
doaj   +1 more source

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

Neuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu, Xiaoling Chen, Xinyi Huang, Quandan Tan, Qing Cao, Yali Yang, Yapeng Lin, Jie Yang   +7 more
wiley   +1 more source

Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Introduction: Ticagrelor might reduce infarct size by exerting a more potent antiplatelet effect or by promoting a potential conditioning stimulus in ST-elevation myocardial infarction (STEMI) patients.
João Pedro Faria MD, Pedro Oliveira PhD, André Alexandre MD, David Sá Couto MD, Ricardo Costa MD, Andreia Campinas MD, André Frias MD, Bruno Brochado MD, Raquel Santos MD, João Silveira MD, Severo Torres MD, André Luz MD, PhD, FESC   +11 more
doaj   +1 more source

Effectiveness and Safety of Ticagrelor Implementation in Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: A Cohort Study in Western Denmark

The Lancet Regional Health. Europe, 2022
Summary: Background: Ticagrelor was introduced in Denmark in 2011 after randomised data showed its superiority over clopidogrel for patients with acute coronary syndrome (ACS). We assessed the effectiveness and safety of ticagrelor implementation in ACS
Pernille Gro Thrane, Kevin Kris Warnakula Olesen, Morten Würtz, Christine Gyldenkerne, Morten Madsen, Lisette Okkels Jensen, Bent Raungaard, Henrik Toft Sørensen, Troels Thim, Steen Dalby Kristensen, Michael Maeng   +10 more
doaj   +1 more source

Update on the Pathophysiology, Aetiology and Management of Central Sleep Apnoea

Respirology, EarlyView.
ABSTRACT Central sleep apnoea (CSA) of the periodic breathing type occurs during the transition between wakefulness and stage 1 and 2 non‐REM sleep. In adults at sea level, it occurs most commonly due to advanced heart failure (HF) or chronic opioid use and in ~5% of obstructive sleep apnoea patients initiating CPAP.
Sahan D. Chandrasekara, Matthew T. Naughton   +1 more
wiley   +1 more source

Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis

BMC Cardiovascular Disorders, 2018
Background & Aims Ticagrelor has been acknowledged as a new oral antagonist of P2Y12-adenosine diphosphate receptor, as a strategy with more rapid onset as well as more significant platelet inhibition function in acute coronary syndrome (ACS) patients ...
Dong Wang, Xiao-Hong Yang, Ji-Dong Zhang, Rui-Bin Li, Min Jia, Xiao-Ran Cui   +5 more
doaj   +1 more source

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention

Platelets, 2022
It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in ...
Yue Wang, Beibei Liu, Leilei Chen, Yue Wang, Zhiqiang Wang, Xiaojiang Zhang, Min Suo, Gary S. Mintz, Xiaofan Wu   +8 more
doaj   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source